for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover   Journal of Clinical and Experimental Hepatology
  [SJR: 0.142]   [H-I: 3]   [1 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0973-6883
   Published by Elsevier Homepage  [2812 journals]
  • The Fifth Year of JCEH: The Year of Recognition
    • Authors: Radha K. Dhiman
      First page: 1
      Abstract: The Journal of Clinical and Experimental Hepatology (JCEH) has completed four years of continuous publication since its launch on 25th March 2011, during the annual conference of Indian National Association for the Study of Liver (INASL) held at Chandigarh. JCEH has now, in its fifth year of successful publication, been catalogued in the National Library of Medicine (NLM), with a status of PubMed Central (PMC), thus crossing the first major milestone on its journey towards achieving recognition as a publication, which attracts hepatobiliary research of a high standard.
      Citation: Journal of Clinical and Experimental Hepatology 5, 1 (2015)
      PubDate: 2015-03
      DOI: 10.1016/j.jceh.2015.03.004
      Issue No: Vol. 5, No. 1 (2015)
       
  • Hepatitis C Virus (HCV) Infection in Patients with End Stage Renal
           Disease: A Study from a Tertiary Care Centre in India
    • Authors: Anil Arora; Naresh Bansal, Praveen Sharma, Vikas Singla, Varun Gupta, Pankaj Tyagi, Manish Malik, Ashish Kumar
      Abstract: Hepatitis C Virus (HCV) infection is common in patients with end stage renal disease (ESRD) and is an important cause of liver disease. We describe the demographic, clinical and biochemical profile of these patients from a tertiary care center of north India.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-15
      DOI: 10.1016/j.jceh.2015.04.004
       
  • Recurrent Budd-Chiari Syndrome Presenting with Lower Limb Ulcers
    • Authors: Xingshun Qi; Feifei Wu, Daiming Fan, Guohong Han
      Abstract: In China, most of BCS patients live in poverty so that the early diagnosis and appropriate treatments are delayed. They often has a chronic course with abdominal wall varices and lower limb edema.1 In the present case, lower limb edema is the first sign of recurrent BCS, which primarily results from the obstacle of venous return of the legs, and then it slowly progresses into the stagnant ulcer of lower limbs.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-11
      DOI: 10.1016/j.jceh.2015.04.005
       
  • Rapid Reversal of Liver Steatosis With Life Style Modification in Highly
           Motivated Liver Donors
    • Authors: Narendra S. Choudhary; Neeraj Saraf, Sanjiv Saigal, Dheeraj Gautam, Lipika Lipi, Amit Rastogi, Sanjay Goja, Palat B. Menon, Prashant Bhangui, Sumana K. Ramchandra, Arvinder S. Soin
      Abstract: Liver steatosis is the leading cause of donor rejection in living donor liver transplantation. Rapid weight loss is difficult to achieve in a short period of time, moreover it has been thought to worsen liver histology.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-05-06
      DOI: 10.1016/j.jceh.2015.04.002
       
  • Online-to-print Lags and Baseline Number of Citations in 5 Science
           Citation Index Journals Related to Liver Diseases (2013–2014)
    • Authors: Xingshun Qi; Hongyu Li, Xu Liu, Wenda Xu, Ming Bai, Xiaozhong Guo
      Abstract: To analyze the length of online-to-print lags in 5 science citation index (SCI) journals related to liver diseases and their effect on the number of citations at the date of print publication.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-30
      DOI: 10.1016/j.jceh.2015.04.003
       
  • Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia:
           Case Report and Literature Review
    • Authors: Neil B. Newman; Salma K. Jabbour, Jane Date C. Hon, Joseph J. Berman, Deen Malik, Darren Carpizo, Rebecca A. Moss
      Abstract: Hepatocellular carcinoma (HCC) in non-cirrhotic livers is an uncommon finding and can present insidiously in patients. Another uncommon finding in HCC, and one of poor prognosis, is the presence of paraneoplastic diseases such as hypercalcemia. We report a case of a 66-year-old previous healthy Filipina woman who after routine laboratory evaluation was discovered to have hypercalcemia as the first sign of an advanced HCC without underlying cirrhosis. Because of the patient's relative lack of symptoms, healthy liver function, lack of classical HCC risk factors, and unexpected hypercalcemia, the diagnosis of a paraneoplastic syndrome caused by a noncirrhotic HCC was unanticipated.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-28
      DOI: 10.1016/j.jceh.2015.04.001
       
  • Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese
           Male Mice
    • Authors: Shigeru Nakano; Kenji Katsuno, Masayuki Isaji, Tatsuya Nagasawa, Benjamin Buehrer, Susan Walker, William O. Wilkison, Bentley Cheatham
      Abstract: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are serious conditions and are being diagnosed at an increased rate. The etiology of these hepatic disorders is not clear but involves insulin resistance and oxidative stress. Remogliflozin etabonate (Remo) is an inhibitor of the sodium glucose-dependent renal transporter 2 (SGLT2), and improves insulin sensitivity in type 2 diabetics. In the current study, we examined the effects of Remo in a diet-induced obese mouse model of NAFLD.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-27
      DOI: 10.1016/j.jceh.2015.02.005
       
  • The Riddle of Nonalcoholic Fatty Liver Disease: Progression From
           Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis
    • Authors: Mithun Sharma; Shasikala Mitnala, Ravi K. Vishnubhotla, Rathin Mukherjee, Duvvur N. Reddy, Padaki N. Rao
      Abstract: Nonalcoholic fatty liver (NAFL) is an emerging global epidemic which progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis in a subset of subjects. Various reviews have focused on the etiology, epidemiology, pathogenesis and treatment of NAFLD. This review highlights specifically the triggers implicated in disease progression from NAFL to NASH. The integrating role of genes, dietary factors, innate immunity, cytokines and gut microbiome have been discussed.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-04
      DOI: 10.1016/j.jceh.2015.02.002
       
  • Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for
           Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid
           Virological Response
    • Authors: Ajit Sood; Vandana Midha, Omesh Goyal
      First page: 2
      Abstract: Chronic hepatitis C (CHC) genotype-3 (G-3) patients treated with standard 24-week pegylated interferon plus ribavirin(PEG-RBV) therapy achieve sustained virological response(SVR) rate of 69–82%. Patients who do not achieve rapid virological response(RVR) have lower SVR rate. Data regarding optimal management of this subgroup is scarce. We aimed to determine the most appropriate treatment duration in CHC G-3 patients who do not achieve RVR.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-02-26
      DOI: 10.1016/j.jceh.2015.02.003
       
  • Clinical and Biochemical Profile of Tuberculosis in Patients with Liver
           Cirrhosis
    • Authors: Praveen Sharma; Pankaj Tyagi, Vikas Singla, Naresh Bansal, Ashish Kumar, Anil Arora
      First page: 8
      Abstract: There is paucity of data on tuberculosis and antituberculous therapy (ATT) induced hepatotoxicity in patients with chronic liver disease.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-02-05
      DOI: 10.1016/j.jceh.2015.01.003
       
  • Study of the Effects of Cyclooxygenase-2 Inhibitor on the Promotion of
           Hepatic Tumorigenesis in Rats Fed a High Fat Diet
    • Authors: Magda Hamzawy; Laila Elsaid, Asmaa Shams, Laila Rashid, Soheir Mahfouz, Nivin Sharawy
      First page: 14
      Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. The highest prevalence of hepatitis is an important risk factor contributing to development of HCCs. However, an increasing number of cases are associated metabolic disease and steatohepatitis. Inflammation associated with many liver disease, seems to be a necessary pre-requisite for successful tumor initiation. Mechanisms that link high fat diet and inflammation initial stage of HCC are not completely understood.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-01-29
      DOI: 10.1016/j.jceh.2014.12.010
       
  • Portal Vein Thrombosis
    • Authors: Yogesh K. Chawla; Vijay Bodh
      First page: 22
      Abstract: Portal vein thrombosis is an important cause of portal hypertension. PVT occurs in association with cirrhosis or as a result of malignant invasion by hepatocellular carcinoma or even in the absence of associated liver disease. With the current research into its genesis, majority now have an underlying prothrombotic state detectable. Endothelial activation and stagnant portal blood flow also contribute to formation of the thrombus. Acute non-cirrhotic PVT, chronic PVT (EHPVO), and portal vein thrombosis in cirrhosis are the three main variants of portal vein thrombosis with varying etiological factors and variability in presentation and management.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-26
      DOI: 10.1016/j.jceh.2014.12.008
       
  • Pregnancy and Vascular Liver Disease
    • Authors: Julien Bissonnette; François Durand, Emmanuelle de Raucourt, Pierre-François Ceccaldi, Aurélie Plessier, Dominique Valla, Pierre-Emmanuel Rautou
      First page: 41
      Abstract: Vascular disorders of the liver frequently affect women of childbearing age. Pregnancy and the postpartum are prothrombotic states. Pregnancy seems to be a trigger for Budd–Chiari syndrome in patients with an underlying prothrombotic disorder. Whether pregnancy is a risk factor for other vascular liver disorders is unknown.In women with a known vascular liver disorder and a desire for pregnancy, stabilisation of the liver disease, including the use of a portal decompressive procedure when indicated, should be reached prior to conception.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-01-20
      DOI: 10.1016/j.jceh.2014.12.007
       
  • Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position
           Paper of the Indian National Association for the Study of the Liver,
           Endocrine Society of India, Indian College of Cardiology and Indian
           Society of Gastroenterology
    • Authors: Ajay Duseja; Shivaram P. Singh, Vivek A. Saraswat, Subrat K. Acharya, Yogesh K. Chawla, Subhankar Chowdhury, Radha K. Dhiman, Rohinivilasam V. Jayakumar, Kaushal Madan, Sri P. Misra, Hrudananda Mishra, Sunil K. Modi, Arumugam Muruganathan, Banshi Saboo, Rakesh Sahay, Rajesh Upadhyay
      First page: 51
      Abstract: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome. Prevalence of metabolic risk factors including diabetes mellitus, obesity, etc. is rapidly increasing in India putting this population at risk for NAFLD. Patients with NAFLD are at increased risk for liver-related morbidity and mortality and also cardiovascular disease risk and increased incidence of diabetes mellitus on long-term follow-up. Management of patients with NAFLD may require a multi-disciplinary approach involving not only the hepatologists but also the internists, cardiologists, and endocrinologists.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-26
      DOI: 10.1016/j.jceh.2015.02.006
       
  • Amoebic Liver Abscess with Hepatic Artery Pseudoaneurysm: Successful
           Treatment by Interventional Radiology
    • Authors: Ajit K. Yadav; Saumya Gupta, Sudarsan Hariprasad, Ashish Kumar, Samarjit S. Ghuman, Arun Gupta
      First page: 86
      Abstract: Amoebic liver abscess is most common extra-intestinal presentation of amoebiasis. It is rarely complicated with vascular involvement including thrombosis of hepatic vein or IVC and pseudo-aneurysm of hepatic artery. We describe a case of hepatic artery pseudo-aneurysm as a complication of amoebic liver abscess treated with percutaneous embolization.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-01-16
      DOI: 10.1016/j.jceh.2014.12.009
       
  • Intrahepatic Cholangiocarcinoma Masquerading as Liver Abscess
    • Authors: Vinit Shah; Anil Arora, Pankaj Tyagi, Praveen Sharma, Naresh Bansal, Vikas Singla, Rinkesh K. Bansal, Varun Gupta, Ashish Kumar
      First page: 89
      Abstract: Malignancy masquerading as liver abscess, and presenting with fever, is mainly described in patients with colorectal cancers with liver metastasis. Primary liver tumors such as hepatocellular carcinoma or intrahepatic cholangiocarcinoma presenting as non-resolving liver abscess is extremely uncommon and carries a dismal prognosis. We present a rare case of non-resolving liver abscess as a presenting manifestation of intrahepatic cholangiocarcinoma.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-02-02
      DOI: 10.1016/j.jceh.2014.12.006
       
  • Abdominal Pain Following Drug-eluting Bead Transarterial Chemoembolization
    • Authors: Abhinav Vasudevan; Manfred Spanger, John S. Lubel
      First page: 93
      Abstract: A 60 year old male presented with a two day history of fevers and right upper quadrant pain. His past medical history was significant for Child Pugh B cirrhosis secondary to chronic hepatitis B and he had received drug-eluting bead transarterial chemoembolization (DEB-TACE) for a 14 mm segment 7 hepatocellular carcinoma three weeks prior to this presentation. His other co-morbidities included a non-occlusive chronic portal vein thrombosis and stage III chronic kidney disease related to previous obstructive uropathy and nephrolithiasis.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-20
      DOI: 10.1016/j.jceh.2015.01.001
       
  • Antibiotics in Acute Liver Failure (ALF)
    • Authors: Shalimar
      First page: 95
      Abstract: Constantine J. Karvellas,* Jorge Cavazos, ‡ Holly Battenhouse, § Valerie Durkalski, § Jody Balko, ‡ Corron Sanders, ‡ and William M. Lee, ‡ for the US Acute Liver Failure Study Group. Effects of Antimicrobial Prophylaxis and Blood Stream Infections in Patients with Acute Liver Failure: A Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2014 Nov; 12(11):1942–9.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-11
      DOI: 10.1016/j.jceh.2015.01.004
       
  • Hepatobiliary Quiz—13 (2015)
    • Authors: Sahaj Rathi; Radha K. Dhiman
      First page: 98
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-04-01
      DOI: 10.1016/j.jceh.2015.03.001
       
  • Hepatobiliary Quiz—13 (2015)
    • Authors: Sahaj Rathi; Radha K. Dhiman
      First page: 100
      Abstract: Liver cells are the sole site of synthesis of albumin. Usual daily production is about 10–15 g per day, which may be increased 3–4 fold when required. Of the total body albumin, 30%–40% is retained in the intravascular compartment, while the rest 60–70% remains in the interstitial spaces.1 The half-life of albumin is 12.7–18.2 days in a young healthy adult. However, circulatory half-life of albumin is approximately 16–18 h as about 5% of albumin is exchanged between intravascular and interstitial spaces every hour.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-30
      DOI: 10.1016/j.jceh.2015.03.002
       
  • Abdominal Pain Following Drug-Eluting Bead Transarterial Chemoembolisation
    • Authors: Abhihav Vasudevan; Manfred Spanger, John S. Lubel
      First page: 105
      Abstract: Acute ischemic cholecystitis following DEB TACE.
      Citation: Journal of Clinical and Experimental Hepatology (2015)
      PubDate: 2015-03-20
      DOI: 10.1016/j.jceh.2015.01.002
       
  • Acute Portal Vein Thrombosis, No Longer a Contraindication for
           Transjugular Intrahepatic Porto-Systemic Shunt (TIPS) Insertion
    • Authors: Suraj Mammen; Shyamkumar N. Keshava, Sajith Kattiparambil
      Abstract: Portal vein thrombosis, once considered as a contraindication to transjugular intrahepatic porto-systemic shunt (TIPS) is now considered as an indication. We report a case with clinical and technical success in a patient with Budd Chiari syndrome and acute portal venous thrombosis. Though it is a well-established option, with the best of our knowledge, we could not find a report from India.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-09-20
      DOI: 10.1016/j.jceh.2014.08.008
       
  • Decellularization and Cell Seeding of Whole Liver Biologic Scaffolds
           Composed of Extracellular Matrix
    • Authors: Denver M. Faulk; Justin D. Wildemann, Stephen F. Badylak
      First page: 69
      Abstract: The definitive treatment for patients with end-stage liver disease is orthotropic transplantation. However, this option is limited by the disparity between the number of patients needing transplantation and the number of available livers. This issue is becoming more severe as the population ages and as the number of new cases of end-stage liver failure increases. Patients fortunate enough to receive a transplant are required to receive immunosuppressive therapy and must live with the associated morbidity.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-03-31
      DOI: 10.1016/j.jceh.2014.03.043
       
  • Acute-on-Chronic Liver Failure: Recent Concepts
    • Authors: Richard Moreau; Rajiv Jalan, Vicente Arroyo
      First page: 81
      Abstract: A proportion of patients hospitalized for an acute complication of cirrhosis are at high risk of short-term death. The term Acute-on-Chronic Liver Failure (ACLF) is used to characterize these patients. Until recently there was no evidence-based definition of ACLF. In 2013 a definition has been proposed based on results of a large prospective observational European study, called “European Association for the Study of the Liver (EASL)–Chronic Liver Failure (CLIF) Consortium Acute-on-Chronic Liver Failure in Cirrhosis (CANONIC)” study.
      Citation: Journal of Clinical and Experimental Hepatology (2014)
      PubDate: 2014-10-03
      DOI: 10.1016/j.jceh.2014.09.003
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015